Open AccessEvaluation of a treatment strategy for optimising preoperative chemoradiotherapy in stage III non-small-cell lung cancer☆☆☆
Author(s) -
Erik C.J. Phernambucq,
F. Spoelstra,
Marinus A. Paul,
Suresh Senan,
Christian F. Melissant,
Pieter E. Postmus,
Egbert F. Smit
Publication year - 2009
Publication title -
european journal of cardio-thoracic surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.303
H-Index - 133
eISSN - 1873-734X
pISSN - 1010-7940
DOI - 10.1016/j.ejcts.2009.05.025
Subject(s) - medicine , mediastinoscopy , chemoradiotherapy , radiation therapy , stage (stratigraphy) , induction chemotherapy , lung cancer , gemcitabine , surgery , esophageal cancer , esophagectomy , radiology , cancer , oncology , chemotherapy , paleontology , biology
Concurrent chemoradiotherapy is standard of care in stage III non-small-cell lung cancer, although surgery may be beneficial in selected patients in whom induction therapy has achieved 'down-staging' of mediastinal nodal disease. Previous studies incorporated treatment 'splits' for re-evaluation, and such gaps lead to poorer survival in patients undergoing chemoradiotherapy. We describe the outcome of a treatment strategy to limit the duration of treatment splits.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom